Revenue, Number of Agreements with International Partners for Commercialization in International Markets

No definition available.

Name:	cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets
Namespace Prefix:	cpix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Revenue.

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionMilestoneMethodAgreedAdditionalAmount
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Receive payments of licensing agreement.

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionMilestoneMethodAgreedAmount
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Future Revenue Earned Upon Achieving MIlestone

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	cpix_RevenuesTextualAbstract
Namespace Prefix:	cpix_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Revenues (Details Textual) (USD $)	3 Months Ended					3 Months Ended		12 Months Ended			3 Months Ended
Revenues (Details Textual) (USD $)	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013 Acetadote, Generic	Mar. 31, 2013 Acetadote and Caldolor	Mar. 31, 2013 Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval Acetadote and Caldolor	Mar. 31, 2013 Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners agreement	Mar. 31, 2012 Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. Acetadote and Caldolor	Dec. 31, 2012 Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. Acetadote and Caldolor	Dec. 31, 2012 Maximum Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval	Dec. 31, 2012 Maximum Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners Milestone Method Future Revenue, Payments Based on Total and Annual Product Sales	Mar. 31, 2013 International	Mar. 31, 2012 International
Revenues (Textual) [Abstract]
Share of product revenue from generic sales			$ 3,000,000
Number of agreements with international partners for commercialization in international markets						3
Revenue recognized from license agreement						400,000	500,000	700,000
Other revenues, milestone method, future revenue upon achieving milestones									400,000	3,000,000
Agreed future payments under licensing agreement once milestone achieved				700,000
Additional milestone payments to be received					1,100,000
Product sales (less than $0.1 million for each of the three months ended March 31, 2013 and 2012)	$ 10,258,132	$ 10,256,212									$ 100,000	$ 100,000